CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...
Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have ...
March 9, 2026Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
The optimal duration of adjuvant imatinib has yet to be determined, and clinical trials are ongoing to address this. KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced ...
GIST patients should seek specialists for accurate diagnosis and treatment, as vague symptoms complicate initial identification. Tissue biopsy and molecular testing are essential for confirming GIST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results